Pharmacoeconomic evaluations in the treatment of actinic keratoses. (June 2017)

• Record Type: Journal Article
• Authors: Tolley, Keith; Argenziano, Giuseppe; Calzavara-Pinton, Pier Giacomo; Larsson, Thomas; Ryttig, Lasse
• Is Part Of: International journal of immunopathology and pharmacology. Volume 30:Number 2(2017)
• Page Start: 178
• Page End: 181
• Publication Date: 2017-06
• Subjects: actinic keratosis (AK) -- cost-effectiveness -- diclofenac -- ingenol mebutate -- pharmacoeconomic; Immunopathology -- Periodicals; Pharmacology -- Periodicals; Inflammation -- Periodicals; 615.1
• DOI: 10.1177/0394632017697719
• Languages: English
• ISSNs: 0394-6320

Abstract

Actinic keratoses (AKs) develop as a consequence of chronic ultraviolet (UV) exposure and exist on a continuum with squamous cell carcinoma (SCC). As one of the most common conditions treated by dermatologists, AK places a significant burden on patients and the healthcare system. A range of treatments are used, including topical treatments that target the visible and subclinical lesions. The goal of such therapies is to achieve complete clearance of AKs and eliminate the risk of progression to SCC. Robust meta-analyses of trial data can provide valuable information for the optimal management of AK and cost-effectiveness evaluations of topical treatments, such as ingenol mebutate gel and diclofenac. These outcomes can facilitate prescribing physicians' decisions and shape therapeutic guidelines. Peer-reviewed meta-analysis publications and treatment guidelines favoured ingenol mebutate efficacy over diclofenac and the relative cost-effectiveness of ingenol mebutate. We discuss and critique recent evidence, from a cost-effectiveness analysis of 3% diclofenac sodium and ingenol mebutate in the treatment of AK in Italy, which has challenged this view.